BRPI1010086A2 - método e produtos para tratamento de doenças - Google Patents

método e produtos para tratamento de doenças

Info

Publication number
BRPI1010086A2
BRPI1010086A2 BRPI1010086A BRPI1010086A BRPI1010086A2 BR PI1010086 A2 BRPI1010086 A2 BR PI1010086A2 BR PI1010086 A BRPI1010086 A BR PI1010086A BR PI1010086 A BRPI1010086 A BR PI1010086A BR PI1010086 A2 BRPI1010086 A2 BR PI1010086A2
Authority
BR
Brazil
Prior art keywords
products
treatment method
disease treatment
disease
treatment
Prior art date
Application number
BRPI1010086A
Other languages
English (en)
Inventor
Bar-Or David
Original Assignee
Dmi Acquisition Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dmi Acquisition Corp filed Critical Dmi Acquisition Corp
Publication of BRPI1010086A2 publication Critical patent/BRPI1010086A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
    • B65D81/32—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents for packaging two or more different materials which must be maintained separate prior to use in admixture

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Mechanical Engineering (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
BRPI1010086A 2009-06-22 2010-06-22 método e produtos para tratamento de doenças BRPI1010086A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21918509P 2009-06-22 2009-06-22
US32299010P 2010-04-12 2010-04-12
PCT/US2010/039461 WO2010151531A1 (en) 2009-06-22 2010-06-22 Methods and products for treatment of diseases

Publications (1)

Publication Number Publication Date
BRPI1010086A2 true BRPI1010086A2 (pt) 2018-02-06

Family

ID=43354873

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1010086A BRPI1010086A2 (pt) 2009-06-22 2010-06-22 método e produtos para tratamento de doenças

Country Status (10)

Country Link
US (3) US20100323991A1 (pt)
EP (1) EP2445350A4 (pt)
AU (1) AU2010264525B2 (pt)
BR (1) BRPI1010086A2 (pt)
CA (1) CA2765883A1 (pt)
IL (1) IL217073A (pt)
MX (1) MX2011013984A (pt)
SG (2) SG177302A1 (pt)
WO (1) WO2010151531A1 (pt)
ZA (1) ZA201109449B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5544458B2 (ja) * 2005-07-12 2014-07-09 アンピオ ファーマシューティカルズ，インコーポレイテッド 疾病を治療するための医薬製品の製造においてトリロスタンｉｉｉを使用する方法及びトリロスタンｉｉｉを含む医薬製品
JP5833549B2 (ja) 2009-06-22 2015-12-16 アンピオ ファーマシューティカルズ，インコーポレイテッド 血管透過性亢進を抑制するためのダナゾールを含む製薬組成物
SG177302A1 (en) * 2009-06-22 2012-02-28 Dmi Acquisition Corp Methods and products for treatment of diseases
MX340734B (es) 2011-01-25 2016-07-22 Novartis Ag Sistemas y metodos de captura y formacion de imagenes de movimiento para uso medico.
US9532866B2 (en) * 2012-03-15 2017-01-03 L&C Bio Co., Ltd. Acellular dermal graft
US20150258168A1 (en) * 2012-09-12 2015-09-17 Oklahoma Medical Research Foundation Modulation of podoplanin mediated platelet activation
US9603890B2 (en) 2012-12-03 2017-03-28 Vascular Biosciences Methods for increasing the selective efficacy of gene therapy using CAR peptide and heparan-sulfate mediated macropinocytosis
CN104968350A (zh) 2012-12-19 2015-10-07 安皮奥制药股份有限公司 疾病的治疗方法
US10449209B2 (en) 2015-04-29 2019-10-22 Arterez, Llc Methods and compositions for reversing disruption of the glycocalyx, inflammation, and oxidative damage
EP3703679A1 (en) 2017-11-04 2020-09-09 Massachusetts Institute Of Technology Compositions and methods to increase muscular strength

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3135743A (en) * 1960-06-29 1964-06-02 Sterling Drug Inc Steroido[2. 3-d]isoxazoles and preparation thereof
US4160027A (en) * 1977-12-20 1979-07-03 Sterling Drug Inc. Steroid cyanoketones and intermediates
US4994443A (en) * 1982-12-20 1991-02-19 The Children's Medical Center Corporation Inhibition of angiogenesis
US5714481A (en) * 1983-08-02 1998-02-03 Research Corporation Technologies, Inc. Derivatives of 5-androsten-17 ones and 5-androstan-17-ones
US4837212A (en) * 1984-11-15 1989-06-06 University Of Miami Treatment of hemolytic anemia with danazol
US4975537A (en) * 1985-10-23 1990-12-04 The Upjohn Company Δ9(11) -angiostatic steroids
DE3738620A1 (de) * 1987-11-13 1989-05-24 Luderschmidt Christoph Verwendung von ethisterone zur topischen behandlung von akne oder androgenetischer alopezie
US5407926A (en) * 1987-12-29 1995-04-18 Alcon Laboratories, Inc. Ophthalmic composition
US5990099A (en) * 1988-10-31 1999-11-23 Alcon Laboratories, Inc. Angiostatic agents and methods and compositions for controlling ocular hypertension
US5372996A (en) * 1989-03-10 1994-12-13 Endorecherche, Inc. Method of treatment of androgen-related diseases
AU5856090A (en) * 1989-07-07 1991-02-06 Endorecherche Inc. Androgen derivatives for use in the inhibition of sex steroid activity
US5972922A (en) * 1990-06-11 1999-10-26 Alcon Laboratories, Inc. Steroids which inhibit angiogenesis
JP3328729B2 (ja) * 1991-06-18 2002-09-30 ラボラトアール、テラメックス、エス、ア 抗緑内障薬剤組成物
US5679666A (en) * 1991-11-22 1997-10-21 Alcon Laboratories, Inc. Prevention and treatment of ocular neovascularization by treatment with angiostatic steroids
US5770592A (en) * 1991-11-22 1998-06-23 Alcon Laboratories, Inc. Prevention and treatment of ocular neovascularization using angiostatic steroids
JPH07508716A (ja) * 1992-04-21 1995-09-28 ザ　スキーペンズ　アイ　リサーチ　インスティテュート，インコーポレイテッド シェーグレン症候群における眼のアンドロゲン療法
US5770589A (en) * 1993-07-27 1998-06-23 The University Of Sydney Treatment of macular degeneration
US5646136A (en) * 1994-01-04 1997-07-08 Duke University Methods of inhibiting angiogenesis and tumor growth, and treating ophthalmologic conditions with angiostatic and therapeutic steroids
NZ283658A (en) * 1994-04-04 1999-09-29 William R Freeman Compositions and treatment of increased intraocular pressure with phosphonyl-alkyloxy-pyrimidines/purines (nucleosides)
US5929111A (en) * 1996-12-18 1999-07-27 Alcon Laboratories, Inc. A-seco steroids effective at treating ophthalmic pathological neovascularization and controlling intraocular pressure
US5993856A (en) * 1997-01-24 1999-11-30 Femmepharma Pharmaceutical preparations and methods for their administration
WO1998043647A1 (en) * 1997-03-28 1998-10-08 Massachusetts Institute Of Technology, Inc. Regulation of amyloid precursor protein (app) expression by estrogenic compounds
US6011023A (en) * 1997-08-27 2000-01-04 Alcon Laboratories, Inc. Angiostatic steroids
US6645954B2 (en) * 1998-04-09 2003-11-11 Multimed Limited Compositions comprising ethisterone or its derivatives
US20040063719A1 (en) * 1998-08-26 2004-04-01 Queen's University At Kingston Combination therapy using antihypertensive agents and endothelin antagonists
EP1022027A1 (en) * 1999-01-22 2000-07-26 Applied Research Systems ARS Holding N.V. Tumor necrosis factor antagonists and their use in endometriosis
US6610674B1 (en) * 1999-09-28 2003-08-26 University Of Pennsylvania Method of treating inflammatory conditions with progesterone analogs
CA2383499C (en) * 1999-10-21 2009-11-24 Alcon Universal Ltd. Drug delivery device
EP1225879A2 (en) * 1999-10-22 2002-07-31 Orbon Corporation Ophthalmic formulation of dopamine antagonists
US6562369B2 (en) * 1999-12-16 2003-05-13 Dermatrends, Inc. Transdermal administration of androgenic drugs hydroxide-releasing agents as permeation enhancers
AU2001230864A1 (en) * 2000-01-12 2001-07-24 Merck And Co., Inc. Inhibitors of prenyl-protein transferase
US20020055512A1 (en) * 2000-01-21 2002-05-09 Cortendo Ab. Compositions for delivery of a cortisol antagonist
US20040082557A1 (en) * 2001-01-26 2004-04-29 Wajszczuk Charles Paul Methods for treating estrogen-dependent disorders
GB2375958B (en) * 2001-04-09 2005-03-02 George Margetts The use of steroids to lower the levels of cortisol
US6936599B2 (en) * 2001-04-25 2005-08-30 The Regents Of The University Of California Estriol therapy for multiple sclerosis and other autoimmune diseases
US20030003144A1 (en) * 2001-05-01 2003-01-02 Keller Brian C. Sustained release formulations for nifedipine, dextromethorphan, and danazol
FR2825277B1 (fr) * 2001-05-30 2004-10-15 Oreal Composition cosmetique et/ou dermatologique et/ou pharmaceutique contenant au moins un compose ihnibiteur de l'enzime 3, b-hsd
US20030232798A1 (en) * 2001-06-12 2003-12-18 Yadon Arad Adrenal enzyme inhibitors
US20030050291A1 (en) * 2001-06-12 2003-03-13 Yadon Arad Adrenal enzyme inhibitors
US20040219208A1 (en) 2001-08-03 2004-11-04 Ryu Kawamura Sustained-release medicines
EP2298315A1 (en) * 2002-08-28 2011-03-23 Harbor BioSciences, Inc. Therapeutic treatment methods
NZ540885A (en) * 2002-12-20 2009-02-28 Chakshu Res Inc Ophthalmic formulation for the prevention and treatment of ocular conditions
GB0313612D0 (en) 2003-06-12 2003-07-16 Novartis Ag Organic compounds
WO2005053660A2 (en) * 2003-12-03 2005-06-16 Lifecycle Pharma A/S Pharmaceutical compositions comprising danazol
GB0329667D0 (en) * 2003-12-22 2004-01-28 King S College London Core 2 GlcNAc-T inhibitor
US20050143362A1 (en) * 2003-12-31 2005-06-30 Mclane Michael W. Danazol for treatment of hypogonadism in the adult male
US7442681B2 (en) * 2004-02-10 2008-10-28 University Of Virginia Patent Foundation Method of inhibiting vascular permeability
US20050244469A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
CA2572223C (en) * 2004-06-25 2014-08-12 The Johns Hopkins University Angiogenesis inhibitors
JP5544458B2 (ja) * 2005-07-12 2014-07-09 アンピオ ファーマシューティカルズ，インコーポレイテッド 疾病を治療するための医薬製品の製造においてトリロスタンｉｉｉを使用する方法及びトリロスタンｉｉｉを含む医薬製品
US8404643B2 (en) * 2005-12-22 2013-03-26 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
US20070173538A1 (en) * 2005-12-23 2007-07-26 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
US8071779B2 (en) * 2006-12-18 2011-12-06 Inspire Pharmaceuticals, Inc. Cytoskeletal active rho kinase inhibitor compounds, composition and use
ES2493641T3 (es) * 2007-06-28 2014-09-12 Cydex Pharmaceuticals, Inc. Administración nasal de soluciones acuosas de corticosteroides
JP5833549B2 (ja) * 2009-06-22 2015-12-16 アンピオ ファーマシューティカルズ，インコーポレイテッド 血管透過性亢進を抑制するためのダナゾールを含む製薬組成物
SG177302A1 (en) * 2009-06-22 2012-02-28 Dmi Acquisition Corp Methods and products for treatment of diseases

Also Published As

Publication number Publication date
SG177302A1 (en) 2012-02-28
MX2011013984A (es) 2012-06-01
IL217073A (en) 2017-05-29
US20130005699A1 (en) 2013-01-03
AU2010264525B2 (en) 2015-04-02
AU2010264525A1 (en) 2012-01-19
EP2445350A4 (en) 2012-12-26
US20100323991A1 (en) 2010-12-23
CA2765883A1 (en) 2010-12-29
IL217073A0 (en) 2012-02-29
EP2445350A1 (en) 2012-05-02
ZA201109449B (en) 2013-05-29
US20160158250A1 (en) 2016-06-09
SG10201403388SA (en) 2014-10-30
WO2010151531A1 (en) 2010-12-29

Similar Documents

Publication Publication Date Title
BRPI1010086A2 (pt) método e produtos para tratamento de doenças
HUE049880T2 (hu) Anyag és eljárások Her-3-mal összefüggõ betegségek kezelésére vagy megelõzésére
BR112012003745A2 (pt) métodos e produtos para iluminação de tecidos
BR112013013884A2 (pt) métodos de processamento contínuo para produtos biológicos
BR112012001142A2 (pt) método e aparelho para feitura de produtos alimentícios
BR112012000882A2 (pt) Preparação cosmética capilar e método para aplicação.
BR112013007678A2 (pt) método para tratamento de doenças alérgicas
BRPI0813725A2 (pt) Métodos e composições para tratamento de doenças
BR112013018469A2 (pt) dispositivos e métodos para tratamento de tecidos
HUE040445T2 (hu) Antiszensz molekulák és eljárások betegségek kezelésére
BR112012003365A2 (pt) método e dispositivo para a fabricação de objetos de titânio.
BRPI0908026A2 (pt) Métodos para o tratamento de doenças do intestino
PL2482859T3 (pl) Sposób sterylizacji
BR112013013584A2 (pt) endoscópio, e, método
BR112012004979A2 (pt) composições para o tratamento de semente e métodos
BR112012020425A2 (pt) dispositivo e método para tratamento de água
BRPI1013655A8 (pt) dispositivo e método cirúrgico
BR112012015322A2 (pt) propante e método para formar o propante
BRPI1011795A2 (pt) método e aparelho para tratamento de pele fracional.
PT2528699T (pt) Aparelho e processo para tratamento de resíduos
BRPI1008566A2 (pt) métodos e composições para o diagnóstico e tratamento de câncer
BRPI1007600A2 (pt) composições e métodos para tratamento de doenças cardiovasculares
BRPI0924469A2 (pt) método para esterilizar calçados e aparelho para esterilizar calçados
BR112013030381A2 (pt) reagentes e métodos para tratar doença dental
BR112012016364A2 (pt) "método para fabricar produtos embutidos, embutidos e dispositivo de produção de embutidos"

Legal Events

Date Code Title Description
B15I Others concerning applications: loss of priority
B25C Requirement related to requested transfer of rights

Owner name: DMI ACQUISITION CORP. (US)

Free format text: A FIM DE ATENDER A TRANSFERENCIA, REQUERIDA ATRAVES DA PETICAO NO 860140171638 DE 13/10/2014, E NECESSARIO APRESENTAR A TRADUCAO JURAMENTADA DO DOCUMENTO, ALEM DA GUIA DE CUMPRIMENTO DE EXIGENCIA.

Owner name: DMI ACQUISITION CORP. (US)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B25B Requested transfer of rights rejected

Owner name: DMI ACQUISITION CORP. (US)

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]